Radiotherapie des seminomes testiculaires: ce qui a change ces dix dernieres annees. [Radiotherapy of testicular seminoma: changes over the past 10 years]

Details

Serval ID
serval:BIB_60E957678D63
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Radiotherapie des seminomes testiculaires: ce qui a change ces dix dernieres annees. [Radiotherapy of testicular seminoma: changes over the past 10 years]
Journal
Cancer RadioThérapie
Author(s)
Mirimanoff  R. O.
ISSN
1278-3218 (Print)
Publication state
Published
Issued date
11/2003
Volume
7 Suppl 1
Pages
70s-77s
Notes
English Abstract
Journal Article
Review --- Old month value: Nov
Abstract
Radiotherapy is generally considered as the standard treatment for most testicular seminomas. However, there have been substantial changes in the management of these tumours over the past few years. In early seminoma, there is a trend towards a decrease in treatment intensity or even towards therapeutic abstention (i.e. surveillance); whereas in advanced cases, combination chemotherapy is taking over from radiotherapy. In stage I, where cure rates are almost 100%, the limiting of the lymph node area to be irradiated and decrease of the dose to 20-25 Gy was followed by very low long-term toxicity rates, and a very small risk of infertility, without compromising the overall prognosis. Surveillance is an acceptable alternative to postoperative radiotherapy. However, the risk of nodal relapse is around 18-20%. With surveillance, the frequency and duration of follow-up is increased in comparison to the same with postoperative radiotherapy, with higher cost. In stage IIa, radiotherapy remains the standard but recent studies have shown that limiting the nodal volume to the paraortic area is justified as in stage I. In stage IIb and higher, combination chemotherapy is almost always given. However, the association between carboplatin and radiotherapy represents an efficient and well-tolerated alternative. Late tissue damage and the risk of decrease in fertility are minimized with novel radiotherapeutic approaches. However, the occurrence of second cancers in the long term is a matter of concern. It is possible though, that patients with seminoma have a tendency per se to develop second cancers. The prognosis of cryptorchid seminoma and of HCG-producing seminoma has been the subject of controversy but recent large studies have demonstrated that stage for stage, the cure rates are similar to those of other seminomas.
Keywords
Adult Antineoplastic Agents/administration & dosage/therapeutic use Carboplatin/administration & dosage/therapeutic use Chorionic Gonadotropin/secretion Combined Modality Therapy Cryptorchidism/complications Dose Fractionation Follow-Up Studies Humans Infertility, Male/etiology Lymphatic Metastasis Male Multicenter Studies Neoplasm Recurrence, Local Neoplasms, Second Primary/epidemiology Orchiectomy Patient Satisfaction Postoperative Care Prognosis Quality of Life Radiotherapy/adverse effects Radiotherapy Dosage Randomized Controlled Trials Retrospective Studies Risk Factors Seminoma/drug therapy/mortality/pathology/*radiotherapy/secretion/surgery Testicular Neoplasms/drug therapy/mortality/pathology/*radiotherapy/secretion/surgery Testis/pathology Time Factors
Pubmed
Create date
24/01/2008 17:12
Last modification date
20/08/2019 14:18
Usage data